Drugs / IBI3020
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06963281 | Apr 2025 → Dec 2027 expected | cancer | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-04-30 | Innovent Biologics (Suzhou) Co. Ltd. | Innovent Announces First Patient Dosed in Phase 1 Study of IBI3020, Global First-in-class Dual Payload CEACAM5 ADC, in Patients with Advanced Malignancies innoventbio.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IBI3020 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06963281 ↗ |
| Modality | Monoclonal antibody | “Recombinant anti-CEACAM5 monoclonal antibody - dual-payload conjugate for injection” NCT06963281 ↗ |
| Target | CEACAM5 | “anti-CEACAM5 monoclonal antibody” NCT06963281 ↗ |